Conclusion
Though rare, a child with XP requires to be investigated for acute
leukaemia on development of bicytopenia. Tolerance to ALL chemotherapy
was good in our XP paediatric patient except for the transient
derangement of liver function tests, Pseudomonas sepsis and oral
mucositis.
References:
1. Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet
J Rare Dis. 2011;6:70-70.
2. Pintens S, Pierret L, Keymolen K, Gutermuth J, De Raeve L. Xeroderma
pigmentosum and leukaemia in two sisters. Journal of the European
Academy of Dermatology and Venereology : JEADV. 2016;30(10):e42-e43.
3. Oetjen KA, Levoska MA, Tamura D, et al. Predisposition to hematologic
malignancies in patients with xeroderma pigmentosum. Haematologica.
2020;105(4):e144-e146.
4. Janjetovic S, Bacher U, Haalck T, Janning M, Bokemeyer C, Fiedler W.
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum:
discussion of pathophysiological, prognostic, and toxicological aspects.
Acta haematologica. 2013;129(2):121-125.
5. DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum.
J Invest Dermatol. 2012;132(3 Pt 2):785-796.
6. ElMahgoub IR, Gouda HM, Samra MA, Shaheen IA, ElMaraashly AH.
Polymorphisms of xeroderma pigmentosum genes (XPC, XPD, and XPG) and
susceptibility to acute leukemia among a sample of Egyptian patients.
Journal of Hematopathology. 2017;10(1):3-7.
7. Sarasin A, Quentin S, Droin N, et al. Familial predisposition to
TP53/complex karyotype MDS and leukemia in DNA repair-deficient
xeroderma pigmentosum. Blood. 2019;133(25):2718-2724.
8. Godley LA, Shimamura A. Genetic predisposition to hematologic
malignancies: management and surveillance. Blood. 2017;130(4):424-432.
9. Schaffer JV, Orlow SJ. Radiation therapy for high-risk squamous cell
carcinomas in patients with xeroderma pigmentosum: report of two cases
and review of the literature. Dermatology (Basel, Switzerland).
2011;223(2):97-103.
10. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y.
Transcription-coupled nucleotide excision repair as a determinant of
cisplatin sensitivity of human cells. Cancer research.
2002;62(17):4899-4902.
11. Sumiyoshi M, Soda H, Sadanaga N, et al. Alert Regarding
Cisplatin-induced Severe Adverse Events in Cancer Patients with
Xeroderma Pigmentosum. Internal medicine (Tokyo, Japan).
2017;56(8):979-982.